Uniphar’s (UPR) “Buy” Rating Reaffirmed at Shore Capital

Shore Capital restated their buy rating on shares of Uniphar (LON:UPRFree Report) in a report released on Tuesday, MarketBeat.com reports.

Uniphar Trading Up 8.5 %

UPR opened at GBX 218 ($2.76) on Tuesday. Uniphar has a twelve month low of GBX 163 ($2.07) and a twelve month high of GBX 256 ($3.24). The company has a 50-day simple moving average of GBX 183.98 and a 200 day simple moving average of GBX 197.24. The company has a quick ratio of 0.60, a current ratio of 0.90 and a debt-to-equity ratio of 119.48. The stock has a market capitalization of £678.59 million, a price-to-earnings ratio of 15.16 and a beta of 0.75.

Uniphar Company Profile

(Get Free Report)

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Featured Stories

Receive News & Ratings for Uniphar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniphar and related companies with MarketBeat.com's FREE daily email newsletter.